Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

MetaVia Inc.

NASDAQ: MTVA · Life Sciences · 8 alerts · CIK 1638287

Share price
$1.21Close, Nov 16
Market cap
$8.13M
Shares outstanding
6.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MetaVia Inc. filings on SEC EDGAR ↗

9:01 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced the completion of the final patient visit in its Phase 1 Part 3A study of DA-1726, a dual GLP-1/glucagon receptor agonist. The company also highlighted interim Part 3B data showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, with full data from both parts expected in Q1 2027.

9:02 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia presented positive preclinical data at ObesityWeek® 2026 comparing its dual-receptor agonist DA-1726 against retatrutide in diet-induced obese mice. The study showed DA-1726 achieved comparable weight loss with less appetite suppression and superior glucose lowering, while significantly increasing hepatic FGF21 expression. The company plans to advance DA-1726 into a Phase 2 study for MetALD and ALD in the second half of 2027.

8:42 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced additional positive data from Part 3B of its Phase 1 clinical trial of DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks. These results complement previously reported data showing a 68.1% reduction in liver fat and 13.5% weight loss, supporting the drug's advancement into a Phase 2 study for MetALD and ALD planned for late 2027.

9:16 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced positive interim data from Part 3B of its Phase 1 trial for DA-1726, showing a statistically significant 68% placebo-adjusted reduction in liver fat and 13.5% weight loss after 16 weeks. The results support the company's plan to initiate a Phase 2 study in patients with MetALD and ALD in the second half of 2027.

“These are the most compelling clinical data we have generated to date supporting DA-1726’s potential as a liver-focused cardiometabolic therapy. A 68% placebo-adjusted reduction in liver fat after approximately 16 weeks, together with all five participants who entered the study with liver steatosis achieving MRI-PDFF below 5%, provides a strong clinical rationale for expanding DA-1726 into liver disease.”

Hyung Heon Kim, President and Chief Executive Officer

“The next step for DA-1726 is clear. We intend to build on these results by advancing the program into both metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), where there are currently no approved therapies specifically for these patient populations.”

Hyung Heon Kim, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.